"Biology and Genomic Distinctions in Metastatic Urothelial Carcinoma and Upper Tract Urothelial Cancers "
Matthew Galsky, MD, director of genitourinary medical oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai discusses research programs and recent findings that drive closer to providing personalized medicine in the treatments in metastatic urothelial carcinoma and upper tract urothelial cancers.
— Matthew Galsky, MD, Director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press Releases"Dr. Galsky Discusses Combination Immunotherapy In Bladder Cancer"
Jun 29, 2018 View All Press Releases